Table 1.
Association of FXN expression with clinicopathological characteristics in ovarian cancer patients (n = 178)
| Variable | All cases,N(%) | FXN expression |
p value | |
|---|---|---|---|---|
| Low | High | |||
| Age(years) | 0.513 | |||
| ≦50 | 70(39.3) | 35 | 35 | |
| >50 | 108(60.7) | 55 | 53 | |
| FIGO stage | 0.001∗∗ | |||
| I/II | 39(21.9) | 29 | 10 | |
| III/IV | 139(78.1) | 61 | 78 | |
| Tumor grade | 0.011∗ | |||
| I/II | 60(33.7) | 38 | 22 | |
| III | 118(66.3) | 52 | 66 | |
| Ascitic fluid volume(ml) | 0.067 | |||
| <500 | 106(59.6) | 59 | 47 | |
| ≥500 | 72(40.4) | 31 | 41 | |
| Serum CA125(U/ml) | 0.035∗ | |||
| <500 | 86(48.3) | 50 | 36 | |
| ≥500 | 92(51.7) | 40 | 52 | |
χ2 test, ∗∗p < 0.01, ∗p < 0.05.
See also Table S2.